0001367644-26-000065
SEC filingQ1 revenue declined 29.7% to $156.1M from lower ACAM2000® international volumes and TEMBEXA® USG sales timing, driving sharp profitability contraction despite cost-saving initiatives and a stable 53.9% gross margin.
Revenue declined 29.7% year-over-year to $156.1 million in Q1 FY2026, primarily driven by lower ACAM2000® sales due to reduced international volumes and an overall decline in TEMBEXA® sales from lower U.S. Government (USG) volumes attributable to timing, partially offset by higher international TEMBEXA® sales. These dynamics underscore the lumpy nature of government procurement contracts in the medical countermeasures (MCM) segment, where order timing significantly impacts quarterly results and exposes the business to volatility in USG demand cycles.
Gross profit fell 37.1% to $84.1 million, yet the gross margin percentage held steady at 53.9%, as the decrease stemmed from an unfavorable sales mix weighted more heavily toward lower-margin products alongside product absorption-related variances. Management notes that gross margin excludes contracts and grants revenues, with related costs classified as R&D expenses. These pressures were partially offset by higher cost of sales for CNJ-016® (VIGIV), BAT®, and BioThrax® due to greater sales volumes and increased overhead at the Winnipeg facility, though overall production declines there contributed to absorption challenges. Capacity utilization remains a key factor in product sales costs beyond fixed and variable manufacturing expenses.
Operating income plunged 79.0% to $10.5 million, reflecting the gross profit decline partially mitigated by lower selling, general, and administrative (SG&A) expenses. This SG&A reduction was primarily due to decreased professional services, marketing, and administrative support, driven by cost-saving initiatives under the company's ongoing turnaround and transformation efforts. Such discipline provides a buffer against revenue volatility but highlights operational efficiencies as a core focus amid profitability pressures.
Net income decreased 90.0% to $6.8 million, or $0.07 diluted EPS from $1.19, aligning with the broader contraction in topline and margins. Cash flow from operations deteriorated to negative $33.8 million from negative $11.2 million prior year, with free cash flow at negative $36.2 million after $2.4 million in capital expenditures. This intensified cash burn reflects working capital swings, including inventory positioning and receivable dynamics, amid Winnipeg production adjustments.
While cost-saving momentum offers partial protection, the business's heavy reliance on volatile MCM sales, coupled with third-party manufacturing and capacity utilization risks at facilities like Winnipeg, warrants close monitoring. Investors should track USG procurement awards, international demand recovery, and transformation progress for signs of stabilization, as insufficient capital resources may necessitate additional financing options like equity/debt offerings or asset sales.